|Awarded On||August 19, 2020|
|Title||Cytoreductive Bispecific PD-L1/PD-L2 Antibodies Active Across Immune "Hot" and "Cold" Cancers|
|Program||Product Development Research|
|Award Mechanism||Texas Company Product Development Awards|
|Principal Investigator/Program Director||Michael Curran|
|Cancer Sites||All Sites|
*Pending contract negotiation
ImmunoGenesis is a Houston, Texas-based company developing novel drugs with technology spun out of MD Anderson Cancer Center (MDACC). In the last decade, immunotherapy drugs, called checkpoint inhibitors, have revolutionized therapy for many cancers, and new combination therapies continue to evolve. However, only a minority (~45%) of cancer patients are eligible to receive these drugs and among those less than 20% achieve a complete or even partial response. ImmunoGenesis' IMGS-001 is a new type of immunotherapy that for the first time can both benefit the majority (55%) of patients ineligible to receive current drugs, and also has the potential to improve responses in existing indications. ...